Entero Therapeutics Reports Agreement Termination & Officer Changes
Ticker: GRDX · Form: 8-K · Filed: Sep 9, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $5 billion, $300 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, management-change, filing
TL;DR
Entero Therapeutics terminated a key deal and swapped out some execs/directors. Big changes ahead?
AI Summary
Entero Therapeutics, Inc. filed an 8-K on September 9, 2025, reporting the termination of a material definitive agreement and changes in its board and officer composition. The company also filed financial statements and exhibits. Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc. until September 21, 2021.
Why It Matters
The termination of a material agreement could significantly impact Entero Therapeutics' operations and future plans. Changes in directors and officers may signal strategic shifts or governance adjustments.
Risk Assessment
Risk Level: medium — Termination of a material agreement and changes in leadership can introduce uncertainty and potential operational or strategic risks.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- September 9, 2025 (date) — Report Date
- First Wave BioPharma, Inc. (company) — Former Company Name
- September 21, 2021 (date) — Date of Name Change
FAQ
What was the specific material definitive agreement that was terminated?
The filing indicates the termination of a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What were the reasons for the termination of the material definitive agreement?
The provided text does not specify the reasons for the termination of the material definitive agreement.
Who are the specific directors or officers that departed or were elected/appointed?
The filing mentions "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" as an item information, but the specific names are not detailed in the provided text.
What is the nature of the compensatory arrangements for certain officers?
The filing lists "Compensatory Arrangements of Certain Officers" as an item, but the details of these arrangements are not included in the provided text.
What are the key financial statements and exhibits being filed with this 8-K?
The filing states "Financial Statements and Exhibits" are included, but the specific content of these documents is not detailed in the provided text.
Filing Stats: 896 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2025-09-09 16:59:41
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Marke
- $5 billion — e was a principal have raised more than $5 billion in alternative assets and deployed more
- $300 million — rnative assets and deployed more than US$300 million in early and growth-stage investments a
Filing Documents
- tm2525441-1_8k.htm (8-K) — 30KB
- 0001104659-25-088663.txt ( ) — 193KB
- fwbi-20250909.xsd (EX-101.SCH) — 3KB
- fwbi-20250909_lab.xml (EX-101.LAB) — 33KB
- fwbi-20250909_pre.xml (EX-101.PRE) — 22KB
- tm2525441-1_8k_htm.xml (XML) — 4KB
02 Termination of a Material Definitive
Item 1.02 Termination of a Material Definitive Agreement The information set forth in Item 5.02 below regarding the termination of the consulting agreement is incorporated by reference in this Item 1.02.
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Termination of Richard Joel Paolone as Interim Chief Executive Officer and Chairman of the Board On September 3, 2025, the Board of Directors (the "Board") of Entero Therapeutics, Inc. (the "Company") terminated Richard Joel Paolone as Interim Chief Executive Officer of the Company and Chairman of the Board, without cause, effective immediately. Mr. Paolone's termination is not due to any disagreement with the Company regarding its financial reporting, policies or practices. Mr. Paolone continue s to serve as a director on the Board of the Company. On September 3, 2025, in connection with his termination as Interim Chief Executive Officer and Chairman of the Board, the Company terminated the consulting agreement between the Company and Mr. Paolone, dated February 12, 2025. The termination was without cause, effective immediately, and included payment in lieu of the contractual notice period. Appointment of Jason D. Sawyer as Interim Chief Executive Officer On September 4, 2025, Jason D. Sawyer was appointed to serve as Interim Chief Executive Officer of the Company, effective immediately. Mr. Sawyer continues to serve as a director on the Board of the Company. Jason D. Sawyer is a 32-year veteran of the alternative investment industry and currently serves as General Manager of Access Alternative Group S.A., a Nassau, Bahamas-based venture investment and advisory firm. Over his career, Mr. Sawyer and the firms in which he was a principal have raised more than $5 billion in alternative assets and deployed more than US$300 million in early and growth-stage investments across software, fintech, blockchain, biotech, clean tech, natural resources, health and fitness, energy, and consumer products. His prior roles include Principal at Crane Capital Associates and Head of its Absolute Return Strategies Group
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. September 9 , 2025 By: /s/ Jason D. Sawyer Name: Jason D. Sawyer Title: Interim Chief Executive Officer